Ketogenic Diet Eases Parkinson's Pain, Fatigue, Brain Fog in 8 Weeks

A ketogenic diet cut Parkinson’s non-motor symptoms by 41% in just eight weeks in a pilot randomized trial, and the sharpest gains landed where patients feel them most: urinary problems, pain and other sensations, fatigue, daytime sleepiness and cognitive impairment.

The study, run by Matthew C. L. Phillips, Deborah K. J. Murtagh, Linda J. Gilbertson, Fredrik J. S. Asztely and Christopher D. P. Lynch, randomized 47 people with Parkinson’s disease to either keto or a low-fat, high-carbohydrate diet. Forty-four started the diets and 38 finished, an 86% completion rate among those who began. The keto group’s MDS-UPDRS Part I score, the scale’s non-motor daily-living section, fell by 4.58 points, which the authors described as a 41% improvement from baseline. The low-fat group improved by 11%, or 0.99 points.

That matters because MDS-UPDRS Part I is the part of the Parkinson’s exam that captures the stuff families notice outside the movement clinic: sleepiness, fogginess, urinary disruption, pain and day-to-day function. In this trial, those were the symptoms that moved the most. The study did not find between-group differences in Parts II through IV, so the diet’s strongest signal was on non-motor burden rather than the motor exam itself.

The tradeoff was not nothing. The keto group maintained physiological ketosis, but some people had intermittent worsening of tremor and rigidity. The low-fat group, meanwhile, reported excessive hunger more often. That kind of split is exactly why this is not a casual “eat less carbs and see what happens” story. It is a structured intervention with a real adherence burden, and in Parkinson’s, where weight loss, swallowing issues and medication timing can already complicate meals, that burden matters.

A newer 12-week trial published in Frontiers in Neuroscience adds a second layer of interest. In 27 Parkinson’s patients, 16 completed the ketogenic diet and showed significant improvements in motor symptoms, measured by MDS-UPDRS Part III, and non-motor symptoms on the NMSS, alongside gut microbiome shifts including more Enterococcus and Synergistota and less Alloprevotella. That does not settle the case, but it does suggest the diet may be doing more than changing macros on a plate.

Right now, the practical take is simple: keto is not standard Parkinson’s treatment, but it is a conversation worth having with a neurologist and dietitian if pain, fatigue, fog and urinary symptoms are the problem. Track the symptoms that matter most, along with weight, tolerance, constipation, sleepiness and how meals line up with medication. The biggest limits are still obvious: small trials, short follow-up, and safety questions in older patients and anyone with kidney disease or other comorbidities.